Marksans Pharma Dirección

Dirección controles de criterios 1/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Mark Saldanha

Chief Executive Officer (CEO)

₹52.2m

Compensación total

Porcentaje del salario del CEO	92.0%
Permanencia del CEO	8.5yrs
Participación del CEO	43.8%
Permanencia media de la dirección	sin datos
Promedio de permanencia en la Junta Directiva	5.7yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Mark Saldanha en comparación con los beneficios de Marksans Pharma?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	n/a	n/a	₹3b
Sep 30 2023	n/a	n/a	₹3b
Jun 30 2023	n/a	n/a	₹3b
Mar 31 2023	₹52m	₹48m	₹3b
Dec 31 2022	n/a	n/a	₹2b
Sep 30 2022	n/a	n/a	₹2b
Jun 30 2022	n/a	n/a	₹2b
Mar 31 2022	₹38m	₹35m	₹2b
Dec 31 2021	n/a	n/a	₹2b
Sep 30 2021	n/a	n/a	₹2b
Jun 30 2021	n/a	n/a	₹3b
Mar 31 2021	₹10m	₹10m	₹2b
Dec 31 2020	n/a	n/a	₹2b
Sep 30 2020	n/a	n/a	₹2b
Jun 30 2020	n/a	n/a	₹1b
Mar 31 2020	₹10m	₹10m	₹1b
Dec 31 2019	n/a	n/a	₹879m
Sep 30 2019	n/a	n/a	₹834m
Jun 30 2019	n/a	n/a	₹780m
Mar 31 2019	₹10m	₹10m	₹804m
Dec 31 2018	n/a	n/a	₹666m
Sep 30 2018	n/a	n/a	₹582m
Jun 30 2018	n/a	n/a	₹463m
Mar 31 2018	₹12m	₹10m	₹358m

Compensación vs. Mercado: La compensación total de Mark($USD626.10K) está por encima de la media de empresas de tamaño similar en el mercado Indian ($USD381.60K).

Compensación vs. Ingresos: La compensación de Mark ha aumentado más de un 20% en el último año.

CEO

Mark Saldanha (51 yo)

8.5yrs

Permanencia

₹52,161,600

Compensación

Mr. Mark B. Saldanha, M.Sc. (Maths) & (Stat.)., Dip. (Fin. Mgt.) serves as Chief Executive Officer, Promoter and Managing Director of Marksans Pharma Limited, which he joined in October 6, 2005 (alternate...

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Mark Saldanha	Non-Independent Executive Chairman	8.5yrs	₹52.16m	43.8% ₹ 34.2b
Sandra Saldanha	Whole-time Director	9.6yrs	₹7.03m	0.049% ₹ 37.9m
Varddhman Jain	Whole-time Director	5.3yrs	₹15.25m	sin datos
Sunny Sharma	Non-Executive Director & Non-Independent	2.7yrs	sin datos	sin datos
Abhinna Mohanty	Non-Executive & Independent Director	4.8yrs	₹40.00k	sin datos
Shailaja Vardhan	Independent Director	less than a year	sin datos	sin datos
Seetharama Buddharaju	Non-Executive & Independent Director	12.5yrs	₹40.00k	sin datos
Digant Parikh	Non-Executive Independent Director	6.1yrs	₹200.00k	sin datos

5.7yrs

Permanencia media

52.5yo

Promedio de edad

Junta con experiencia: La junta directiva de 524404 se considera experimentada (5.7 años de antigüedad promedio).

Marksans Pharma Dirección

Dirección controles de criterios 1/4

Información clave

Actualizaciones recientes de la dirección

Marksans Pharma Limited Appoints Shailaja Vardhan as an Independent Director

Marksans Pharma Limited, Annual General Meeting, Aug 28, 2023

Insufficient new directors

Marksans Pharma Limited, Annual General Meeting, Aug 29, 2022

Recent updates

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Now 23% overvalued after recent price rise

Marksans Pharma Limited to Report Q3, 2024 Results on Feb 13, 2024

Investor sentiment improves as stock rises 17%

Second quarter 2024 earnings released: EPS: ₹1.84 (vs ₹1.52 in 2Q 2023)

Marksans Pharma Limited to Report Q2, 2024 Results on Nov 09, 2023

Marksans Pharma Limited Appoints Shailaja Vardhan as an Independent Director

Marksans Pharma Ltd. Receives USFDA Approval for Guaifenesin Extended-Release Tablets

Marksans Pharma Limited Recommends Payment of Dividend for the Financial Year 2022-23

Full year 2023 earnings released: EPS: ₹6.39 (vs ₹4.56 in FY 2022)

Marksans Pharma Limited, Annual General Meeting, Aug 28, 2023

Insufficient new directors

Investor sentiment improves as stock rises 16%

Marksans Pharma Limited Announces That It Has Received Final Approval from the Us Food and Drug Administration for Its Abbreviated New Drug Application for Acetaminophen and Ibuprofen Tablets, 250 Mg/125 Mg

Marksans Pharma Limited Approves Declaration of Dividend for the Financial Year 2022-23, Payable on or After 12 June, 2023

Full year 2023 earnings released: EPS: ₹6.41 (vs ₹4.56 in FY 2022)

Marksans Pharma Limited to Report Q4, 2023 Results on May 30, 2023

Third quarter 2023 earnings released: EPS: ₹1.56 (vs ₹1.20 in 3Q 2022)

Marksans Pharma Limited to Report Q3, 2023 Results on Feb 13, 2023

Marksans Pharma Limited announced that it has received funding from OrbiMed Asia IV Mauritius FVCI Limited

Second quarter 2023 earnings released: EPS: ₹1.52 (vs ₹1.11 in 2Q 2022)

Marksans Pharma Limited to Report Q2, 2023 Results on Nov 14, 2022

Marksans Pharma Limited (BSE:524404) entered into a Business Transfer Agreement to acquire Bulk Pharmaceutical Business of Tevapharm India Private Limited.

Marksans Pharma Limited Declares Dividend, Payable on or After 20 September 2022

Upcoming dividend of ₹0.25 per share

Full year 2022 earnings released: EPS: ₹4.56 (vs ₹5.83 in FY 2021)

Marksans Pharma Limited to Report Q1, 2023 Results on Aug 13, 2022

Marksans Pharma Limited, Annual General Meeting, Aug 29, 2022

Marksans Pharma Limited Announces US FDA Approval for Pregabalin Capsules

Marksans Pharma Limited (BSE:524404) announces an Equity Buyback for INR 600 million worth of its shares.

Investor sentiment improved over the past week

Marksans Pharma Limited (BSE:524404) completed the acquisition of Access Healthcare for Medical Products LLC.

Marksans Pharma Recommends Final Dividend for the Financial Year Ended 31st March, 2022

Marksans Pharma Recommends Final Dividend for the Financial Year Ended 31st March, 2022

Full year 2022 earnings: EPS and revenues miss analyst expectations

Marksans Pharma Limited to Report Fiscal Year 2022 Results on May 30, 2022

Marksans Pharma Limited (BSE:524404) has signed agreement to acquire share capital of Access Healthcare for Medical Products LLC for AED 13 million.

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Marksans Pharma Limited to Report Q3, 2022 Results on Feb 11, 2022

Second quarter 2022 earnings released: EPS ₹1.11 (vs ₹1.21 in 2Q 2021)

First quarter 2022 earnings released: EPS ₹1.51 (vs ₹1.20 in 1Q 2021)

Investor sentiment deteriorated over the past week

Marksans Pharma Limited announced that it has received INR 930.999994 million in funding from OrbiMed Asia IV Mauritius FVCI Limited and other investor

Marksans Pharma Limited announced that it expects to receive INR 930.999994 million in funding

Investor sentiment improved over the past week

Full year 2021 earnings released: EPS ₹5.76 (vs ₹2.95 in FY 2020)

Marksans Pharma Limited Recommends Dividend for the Financial Year Ended March 31, 2021

Investor sentiment improved over the past week

New 90-day low: ₹54.05

Third quarter 2021 earnings released: EPS ₹1.42 (vs ₹0.71 in 3Q 2020)

Marksans Pharma Limited to Report Q3, 2021 Results on Feb 08, 2021

New 90-day high: ₹56.85

Market bids up stock over the past week

Second quarter 2021 earnings released: EPS ₹1.21

Metformin Hydrochloride Announces Extended Release Tablets, USP 500 MG & 750 MG

Upcoming Dividend of ₹0.10 Per Share

First quarter earnings released

Marksans Pharma Limited to Report Q1, 2021 Results on Aug 04, 2020

New 90-day high - ₹37.55

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Miembros de la Junta

Permanencia media

Promedio de edad